CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
Poses Threat To Other JAK Inhibitors
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
